Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has earned a consensus rating of “Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Eleven investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have updated their coverage on the stock in […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.03, reports. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative return on equity of 33.10%. The company had revenue of $0.25 million during […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $45.00 target price on the stock. Needham & Company LLC’s price target indicates a potential upside of 149.58% from the company’s […]
Pliant Therapeutics, Inc Expected to Earn Q1 2024 Earnings of ($0 73) Per Share (NASDAQ:PLRX) modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) General Counsel Mike Ouimette sold 4,755 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $17.55, for a total transaction of $83,450.25. Following the completion of the sale, the general counsel now owns 60,443 shares […]